Salih Ehsan: Bradykinin-Mediated Transfusion Reactions in Patients on ACE Inhibitors
Salih Ehsan, Chief Executive Officer at Kulsoom Society of Hematology, shared Caitlin Raymond’s post on LinkedIn:
“Thanks for this information.
When an anemic patient comes to a transfusion center, take a look on the drugs that patient is taking regularly (ACE inhibitors, diuretics).
If the patient is taking ACE inhibitors, be ready for hypotensive transfusion reaction in the middle of transfusion.
Correct measures are:
- stop transfusion
- watch for BP, pulse, respiration, oxygen saturation, temperature, subjective feeling of patient.
If everything is okay, except BP then go for IV fluids (volume expander like normal saline).”
Caitlin Raymond, Assistant Professor of Pathology and Transfusion Medicine at University of Wisconsin-Madison, shared a post on LinkedIn:
“The transfusion reaction with the cleanest workup and the most interesting mechanism.
BP drops 40 points mid-transfusion.
No fever. No rash. No hemolysis.
DAT negative. Everything comes back normal.
This is a hypotensive transfusion reaction — and it’s not immunologic.
It’s pharmacologic.
Here’s what’s happening:
- Transfusion tubing and leukoreduction filters present a negatively charged surface to blood
- That contact activates Factor XII – kallikrein – bradykinin
- Bradykinin is a potent vasodilator with a half-life measured in seconds
- ACE normally clears it — but patients on ACE inhibitors can’t
- Result: bradykinin accumulates, vessels dilate, pressure drops
This is why ACE use is the most consistently identified risk factor for hypotensive transfusion reactions.
It’s not an allergy.
The drug is doing exactly what it was prescribed to do.
Management is straightforward: stop, fluids, recover.
No pre-medications indicated — Benadryl and acetaminophen do nothing for bradykinin-mediated hypotension.
The harder question is how many of these reactions we’re missing.
Hypotension is common in sick patients.
A modest BP dip in a patient on antihypertensives and diuretics may never trigger a workup.
New post on Blood Bytes Beyond.”

Stay updated with Hemostasis Today.
-
Nov 4, 2026, 18:57Connecting Haemophilia Centres, Certifying Treaters, and Improving National Data in Romania – EHC
-
Nov 4, 2026, 18:45Smitirupa Mishra: A Practical Guide to Coagulation Pathway Assessment and Laboratory Interpretation
-
Nov 4, 2026, 15:59Alessandra Bosch: A Successful Patient Day for the Bleeding Disorders Community in Zürich
-
Nov 4, 2026, 15:47Wolfgang Miesbach: Targeting Hepatic Endothelial Cells for Lentiviral Gene Therapy in Haemophilia A
-
Nov 4, 2026, 15:20Augustina Isioma Ikusemoro: Before You Transfuse, Think PBM
-
Nov 4, 2026, 14:23Advancing Hemophilia Care Through Global Research – WFH
-
Nov 4, 2026, 14:12Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery
-
Nov 4, 2026, 13:59Rita Li: ASH 2026 Abstract Achievement Award for Gut Microbiome Research
-
Nov 4, 2026, 13:38Omid Seidizadeh: Improving Access to von Willebrand Disease Diagnosis and Treatment Across Europe